GDF-15 inhibition with ponsegromab improved cancer cachexia symptoms: NEJM
A new study by John Groarke and team found the cachexia decreased when ponsegromab was administered at escalating dosages to patients with cancer cachexia and raised circulating growth differentiation factor 15 (GDF-15) levels. The findings of this study were published in the New England Journal of Medicine.
One frequent cancer consequence that is linked to a higher risk of mortality is cachexia. In cancer cachexia, there is an increase in the amount of the circulating cytokine growth differentiation factor 15. Ponsegromab is a humanized monoclonal antibody that inhibits GDF-15 and was linked to better weight, appetite, and physical activity in addition to decreased serum GDF-15 levels.
And so, individuals with cancer cachexia and a high serum GDF-15 level (≥1500 pg per milliliter) were randomized in a phase 2 randomized, double-blind, 12-week trial in a 1:1:1:1 ratio to either receive ponsegromab at a dose of 100 mg, 200 mg, or 400 mg subcutaneously every 4 weeks for three doses, or receive a placebo. The main outcome measure at 12 weeks was the shift in body weight from the baseline. Digital assessments of physical activity, safety, and symptoms of hunger and cachexia were important secondary end goals.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.